Your browser doesn't support javascript.
loading
Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
Filosto, Massimiliano; Cotti Piccinelli, Stefano; Ravaglia, Sabrina; Servidei, Serenella; Moggio, Maurizio; Musumeci, Olimpia; Donati, Maria Alice; Pegoraro, Elena; Di Muzio, Antonio; Maggi, Lorenzo; Tonin, Paola; Marrosu, Gianni; Sancricca, Cristina; Lerario, Alberto; Sacchini, Michele; Semplicini, Claudio; Bozzoni, Virginia; Telese, Roberta; Bonanno, Silvia; Piras, Rachele; Maioli, Maria Antonietta; Ricci, Giulia; Vercelli, Liliana; Galvagni, Anna; Gallo Cassarino, Serena; Caria, Filomena; Mongini, Tiziana; Siciliano, Gabriele; Padovani, Alessandro; Toscano, Antonio.
Afiliación
  • Filosto M; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy. massimiliano.filosto@unibs.it.
  • Cotti Piccinelli S; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Ravaglia S; Emergency Neurology, IRCCS Mondino Foundation, Pavia, Italy.
  • Servidei S; Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.
  • Moggio M; Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • Musumeci O; Department of Clinical and Experimental Medicine, UOC di Neurologia e Malattie Neuromuscolari, University of Messina, Messina, Italy.
  • Donati MA; Metabolic and Neuromuscular Unit, Meyer Children Hospital, University of Florence, Florence, Italy.
  • Pegoraro E; Neuromuscular Center, Department of Neurosciences, University of Padova, Padua, Italy.
  • Di Muzio A; Department of Neuroscience and Imaging, G. d'Annunzio University, Chieti, Italy.
  • Maggi L; Neurology IV, Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
  • Tonin P; Neurological Clinic, University of Verona, Verona, Italy.
  • Marrosu G; ASL8, Centro Sclerosi Multipla, Cagliari, Italy.
  • Sancricca C; Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.
  • Lerario A; Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • Sacchini M; Metabolic and Neuromuscular Unit, Meyer Children Hospital, University of Florence, Florence, Italy.
  • Semplicini C; Neuromuscular Center, Department of Neurosciences, University of Padova, Padua, Italy.
  • Bozzoni V; Neuromuscular Center, Department of Neurosciences, University of Padova, Padua, Italy.
  • Telese R; Department of Neuroscience and Imaging, G. d'Annunzio University, Chieti, Italy.
  • Bonanno S; Neurology IV, Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
  • Piras R; ASL8, Centro Sclerosi Multipla, Cagliari, Italy.
  • Maioli MA; ASL8, Centro Sclerosi Multipla, Cagliari, Italy.
  • Ricci G; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Vercelli L; Department of Neurosciences Rita Levi Montalcini, University of Torino, Turin, Italy.
  • Galvagni A; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Gallo Cassarino S; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Caria F; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Mongini T; Department of Neurosciences Rita Levi Montalcini, University of Torino, Turin, Italy.
  • Siciliano G; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Padovani A; Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Toscano A; Department of Clinical and Experimental Medicine, UOC di Neurologia e Malattie Neuromuscolari, University of Messina, Messina, Italy.
Adv Ther ; 36(5): 1177-1189, 2019 05.
Article en En | MEDLINE | ID: mdl-30879255
INTRODUCTION: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. METHODS: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0-T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. RESULTS: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0-T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. CONCLUSION: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad del Almacenamiento de Glucógeno Tipo II / Anticuerpos Antiidiotipos / Alfa-Glucosidasas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad del Almacenamiento de Glucógeno Tipo II / Anticuerpos Antiidiotipos / Alfa-Glucosidasas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Italia